U.S. markets closed

Alterity Therapeutics Limited (ATHE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6406+0.0106 (+1.68%)
At close: 03:57PM EDT
0.6300 -0.01 (-1.65%)
After hours: 04:06PM EDT

Alterity Therapeutics Limited

460 Bourke Street
Level 3
Melbourne, VIC 3000
61 3 9349 4906

Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Mr. Geoffrey Paul Kempler B.Sc, B.Sc.Co-Founder & Non-Exec. Chairman956.55kN/A1955
Dr. David A. Stamler M.D.Chief Exec. Officer419.5kN/A1961
Ms. Kathryn J. E. AndrewsChief Financial Officer240.83kN/A1967
Dr. Rudolph Emile Tanzi Ph.D.Chief Scientific Advisor and Member of R&D Advisory BoardN/AN/A1959
Dr. Steven D. TargumChief Medical AdvisorN/AN/AN/A
Dr. Robert ChernyHead of ResearchN/AN/AN/A
Mr. Phillip Allen HainsCompany Sec.N/AN/A1959
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Corporate Governance

Alterity Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.